VEGFA and fibrosis: More recently, a study has demonstrated that VEGF‐C156S treatment exerts multifaceted therapeutic effects to attenuate angiotensin II‐induced cardiac dysfunction by improving cardiac lymphatic function and reducing cardiac fibrosis, inflammation, and arterial hypertension.52